TY - JOUR T1 - New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. AU - Orzelska-Górka,Jolanta, AU - Mikulska,Joanna, AU - Wiszniewska,Anna, AU - Biała,Grażyna, Y1 - 2022/09/13/ PY - 2022/07/28/received PY - 2022/09/09/revised PY - 2022/09/09/accepted PY - 2022/9/23/entrez PY - 2022/9/24/pubmed PY - 2022/9/28/medline KW - aripiprazole KW - asenapine KW - brexpiprazole KW - cariprazine KW - depression KW - lumateperone KW - lurasidone KW - pimavanserin KW - schizophrenia JF - International journal of molecular sciences JO - Int J Mol Sci VL - 23 IS - 18 N2 - Schizophrenia and depression are heterogeneous disorders. The complex pathomechanism of the diseases imply that medication responses vary across patients. Many psychotropic drugs are available but achieving optimal therapeutic effect can be challenging. The evidence correlates well with clinical observations, suggesting that new atypical antipsychotic drugs are effective against negative and cognitive symptoms of schizophrenia, as well as against affective symptoms observed in depression. The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. We have first provided a brief overview of the major neurobiological underpinnings of schizophrenia and depression. We then shortly discuss efficacy, safety and limitations of ongoing pharmacotherapy used in depression and schizophrenia. Mainly, we have focused this review on the therapeutic potential of new atypical antipsychotic drugs-currently existing-to be effective in psychotic, as well as in affective disorders. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/36142523/New_Atypical_Antipsychotics_in_the_Treatment_of_Schizophrenia_and_Depression_ DB - PRIME DP - Unbound Medicine ER -